July 3, 2015
Recommended Topic Related To:

Humalog

"More than 29 million people in the United States have diabetes, up from the previous estimate of 26 million in 2010, according to a report released today by the Centers for Disease Control and Prevention. One in four people with diabetes doe"...

Humalog




Indications
Dosage
How Supplied

INDICATIONS

HUMALOG is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

DOSAGE AND ADMINISTRATION

Important Administration Instructions

  • Always check insulin labels before administration [see WARNINGS AND PRECAUTIONS].
  • Inspect HUMALOG visually before use. It should appear clear and colorless. Do not use HUMALOG if particulate matter or coloration is seen.
  • Do NOT mix HUMALOG U-100 with other insulins when administering using a continuous subcutaneous infusion pump.
  • Do NOT transfer HUMALOG U-200 from the KwikPen to a syringe for administration [see WARNINGS AND PRECAUTIONS].
  • Do NOT perform dose conversion when using either the HUMALOG U-100 or U-200 KwikPens. The dose window shows the number of insulin units to be delivered and no conversion is needed.
  • Do NOT mix HUMALOG U-200 with any other insulins.
  • Do NOT administer HUMALOG U-200 using a continuous subcutaneous infusion pump (i.e., insulin pump).
  • Do NOT administer HUMALOG U200 intravenously.

Route Of Administration

Subcutaneous Injection: HUMALOG U-100 or U-200
  • Administer the dose of HUMALOG U-100 or HUMALOG U-200 within fifteen minutes before a meal or immediately after a meal by injection into the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks. To reduce the risk of lipodystrophy, rotate the injection site within the same region from one injection to the next [see ADVERSE REACTIONS].
  • HUMALOG administered by subcutaneous injection should generally be used in regimens with an intermediate-or long-acting insulin.
Continuous Subcutaneous Infusion (Insulin Pump); HUMALOG U-100 ONLY
  • Do NOT administer HUMALOG U-200 using a continuous subcutaneous infusion pump.
  • Administer HUMALOG U-100 by continuous subcutaneous infusion into the subcutaneous tissue of the abdominal wall. Rotate infusion sites within the same region to reduce the risk of lipodystrophy [see ADVERSE REACTIONS].
  • Follow healthcare provider recommendations when setting basal and meal time infusion rate.
  • Do NOT dilute or mix HUMALOG U-100 when administering by continuous subcutaneous infusion.
  • Change HUMALOG U-100 in the pump reservoir at least every 7 days.
  • Change the infusion sets and the infusion set insertion site at least every 3 days.
  • Do NOT expose HUMALOG U-100 in the pump reservoir to temperatures greater than 98.6°F (37°C).
  • Use HUMALOG U-100 in pump systems suitable for insulin infusion [see PATIENT INFORMATION].
Intravenous Administration; HUMALOG U-100 ONLY
  • Do NOT administer HUMALOG U-200 intravenously.
  • Dilute HUMALOG U-100 to concentrations from 0.1 unit/mL to 1.0 unit/mL using 0.9% sodium chloride.
  • Administer HUMALOG U-100 intravenously ONLY under medical supervision with close monitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia [see WARNINGS AND PRECAUTIONS and HOW SUPPLIED/Storage and Handling].

Dosage Information

  • Individualize and adjust the dosage of HUMALOG based on route of administration, the individual's metabolic needs, blood glucose monitoring results and glycemic control goal.
  • Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness [see WARNINGS AND PRECAUTIONS and Use In Specific Populations].
  • Do NOT perform dose conversion when using either the HUMALOG U-100 or U-200 KwikPens. The dose window shows the number of insulin units to be delivered and no conversion is needed.

Dosage Adjustment Due To Drug Interactions

  • Dosage adjustment may be needed when HUMALOG is coadministered with certain drugs [see DRUG INTERACTIONS].
  • Dosage adjustment may be needed when switching from another insulin to HUMALOG [see WARNINGS AND PRECAUTIONS].
  • Instructions for Mixing with Other Insulins

HUMALOG U-100 subcutaneous injection route
  • HUMALOG U-100 may be mixed with NPH insulin preparations ONLY.
  • If HUMALOG U-100 is mixed with NPH insulin, HUMALOG U-100 should be drawn into the syringe first. Injection should occur immediately after mixing.
HUMALOG U-100 continuous subcutaneous infusion route (Insulin Pump)
  • Do NOT mix HUMALOG U-100 with any other insulin.
HUMALOG U-200 subcutaneous injection route
  • Do NOT mix with any other insulin.

HOW SUPPLIED

Dosage Forms And Strengths

HUMALOG 100 units per mL (U-100) is available as:

  • 10 mL vials
  • 3 mL Humalog KwikPen (prefilled)
  • 3 mL cartridges

HUMALOG 200 units per mL (U-200) is available as:

  • 3 mL Humalog KwikPen (prefilled)

HUMALOG 100 units per mL (U-100) is available as:

10 mL vials .................................. 0002-7510-01 (VL-7510)
5 x 3 mL cartridges ..................... 0002-7516-59 (VL-7516)
5 x 3 mL Humalog KwikPen (prefilled) ......... 0002-8799-59 (HP-8799)

HUMALOG 200 units per mL (U-200) is available as:

2 x 3 mL Humalog KwikPen (prefilled) .......... 0002-7712-27 (HP-7712)

Each prefilled KwikPen, cartridge, and reusable pen compatible with Lilly 3 mL cartridges is for use by a single patient. HUMALOG KwikPens, cartridges, and reusable pens compatible with Lilly 3 mL cartridges must never be shared between patients, even if the needle is changed. Patients using HUMALOG vials must never share needles or syringes with another person.

Storage And Handling

Do not use after the expiration date.

Unopened HUMALOG should be stored in a refrigerator (36° to 46°F [2° to 8°C]), but not in the freezer. Do not use HUMALOG if it has been frozen. In-use HUMALOG vials, cartridges, and HUMALOG KwikPen should be stored at room temperature, below 86°F (30°C) and must be used within 28 days or be discarded, even if they still contain HUMALOG. Protect from direct heat and light. See table below:

  Not In-Use (Unopened) Room Temperature (Below 86°F [30°C]) Not In-Use (Unopened) Refrigerated In-Use (Opened) Room Temperature, (Below 86°F [30°C])
HUMALOG U-100
10 mL vial 28 days Until expiration date 28 days, refrigerated/room temperature.
3 mL cartridge 28 days Until expiration date 28 days, Do not refrigerate.
3 mL Humalog KwikPen (prefilled) 28 days Until expiration date 28 days, Do not refrigerate.
HUMALOG U-200
3 mL Humalog KwikPen (prefilled) 28 days Until expiration date 28 days, Do not refrigerate.

Use in an External Insulin Pump

Change the HUMALOG U-100 in the reservoir at least every 7 days, change the infusion sets and the infusion set insertion site at least every 3 days or after exposure to temperatures that exceed 98.6°F (37°C). A HUMALOG 3 mL cartridge used in the D-Tron pumps should be discarded after 7 days, even if it still contains HUMALOG. However, as with other external insulin pumps, the infusion set should be replaced and a new infusion set insertion site should be selected at least every 3 days.

Diluted HUMALOG U-100 for Subcutaneous Injection

Diluted HUMALOG may remain in patient use for 28 days when stored at 41°F (5°C) and for 14 days when stored at 86°F (30°C). Do not dilute HUMALOG contained in a cartridge or HUMALOG used in an external insulin pump.

Preparation And Handling

Diluted HUMALOG U-100 for Subcutaneous Injection

HUMALOG may be diluted with Sterile Diluent for HUMALOG for subcutaneous injection. Diluting one part HUMALOG to nine parts diluent will yield a concentration one-tenth that of HUMALOG (equivalent to U-10). Diluting one part HUMALOG to one part diluent will yield a concentration one-half that of HUMALOG (equivalent to U-50).

Admixture For Intravenous Administration

Infusion bags prepared with HUMALOG U-100 are stable when stored in a refrigerator (2° to 8°C [36° to 46°F]) for 48 hours and then may be used at room temperature for up to an additional 48 hours [see Route of Administration].

Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA. Revised: May 2015

Last reviewed on RxList: 6/30/2015
This monograph has been modified to include the generic and brand name in many instances.

Indications
Dosage
How Supplied

Humalog - User Reviews

Humalog User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Humalog sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Diabetes

Find tips and advances in treatment.